|
|
Post by nemzter on Mar 12, 2014 11:38:29 GMT -5
|
|
|
|
Post by Chris on Mar 12, 2014 12:20:10 GMT -5
No, a bit of a stretch to say this would be more ammo for the upcoming Adcom...
The Adcom's focus will primarily be on the clinical trials. The off chance something like this will be mentioned is during the 3-5 min. limit open public presentation.
-----------
Regarding sterility: The Dreamboat inhaler will be replaced biweekly and cartridges are one-time use -- this does add a level of sanitation.
Since Afrezza is inhaled and not injected, the likelihood of a blood contamination and blood transferred disease is less likely and almost minute.
|
|
